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Serum nitric oxide and peroxynitrite levels in adult
sero-positive rheumatoid arthritis treated with disease
modifying antirheumatic drugs: a preliminary report
Marwan S.M. AL-NIMER1, Samir Abdul-Hassan AL-OBAIDI2, Khalid S. AL-DULAIMI3

Aim: The contribution of inducible nitric oxide synthase (iNOS) to oxidative/nitrative stress is well documented in
inflamed joints. Nitric oxide stimulates the synthesis of proinflammatory mediators and cytotoxic molecules with a
pivotal role in apoptosis at the joint of rheumatoid arthritis. This study aimed to assess the serum levels of nitric oxide
and peroxynitrite in sero positive rheumatoid patients treated with disease modifying antirheumatic drugs.
Materials and methods: Sixteen known patients with sero-positive rheumatoid arthritis fulfilling the criteria of the
American College of Rheumatology and on disease modifying antirheumatic drugs were allocated from the consultant
clinic of rheumatology at Al-Yarmouk Teaching hospital in Baghdad, Iraq, from October 2004 to May 2005. The serum
levels of nitric oxide and peroxynitrite were determined for patients as well as for another 16 healthy individuals serving
as controls.
Results: The mean serum levels of nitric oxide (116.9 μmol) and peroxynitrite (7.3 μmol) were significantly higher than
the controls’ levels of 46 μmol and 2.5 μmol, respectively. Females had non-significantly lower serum nitric oxide and
higher serum peroxynitrite than corresponding males. Patients older than 50 years had non-significantly higher serum
nitric oxide and lower serum peroxynitrite levels than those younger than 50 years old. There was a non-significant
correlation between the serum levels of each of nitrogen species and the duration of disease or erythrocyte sedimentation
rate as a marker of disease activity.
Conclusion: Sero-positive rheumatoid patients treated with disease modifying antirheumatic drugs have significantly
high serum nitric oxide and peroxynitrite levels that are not related to the duration or disease activity.
Key words: Rheumatoid arthritis, nitric oxide, peroxynitrite

Introduction
Nitric oxide (NO) is one of the few gaseous signaling molecules known (1). It is involved in many
physiological and pathological processes within the body, both beneficial and detrimental (2,3).
Appropriate levels of NO production are important in protecting organs from ischemic damage (4),
whereas chronic expression of NO is associated with various malignancies and inflammatory
conditions including juvenile diabetes, multiple sclerosis, arthritis and ulcerative colitis (5,6). Genetic
factors including endothelial nitric oxide synthase (eNOS) were implicated in pathogenesis of
rheumatoid arthritis, and extra-articular manifestations of rheumatoid arthritis were significantly
greater among the carriers (7).
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There is growing evidence that nitrative injury
plays an important role in the pathogenesis of
rheumatoid arthritis. In the experimental model of
rheumatoid arthritis such as rat adjuvant and collagen
induced arthritis, NO production was significantly
elevated (8), and the plasma levels of 3-nitrotyrosine
were significantly correlated with the severity of the
inflammatory response (9). Moreover, in the
experimental model, small doses of NO donors
attenuate joint inflammation and hyperalgesia while
higher doses produce infiltration of mononuclear cells
and cartilage erosion (10). Raised levels of reactive
nitrogen species in serum and synovial fluid have
been reported in patients with rheumatoid arthritis
(11,12).
The correlation between reactive nitrogen species
levels and disease activity is still not confirmed. In
juvenile rheumatoid arthritis, the significant high
serum NO level is correlated with clinical indices of
inflammation and laboratory parameters of disease
activity (12,13), while such a correlation is not definite
in adults (14-16).
In synovial fluid, the NO production is stimulated
by immune complex especially in acute rheumatoid
arthritis and the increased intraarticular NO reflects
abnormalities in the immune system regulation in the
joint (14). The intraarticular granulocytes express
inducible nitric oxide synthase [iNOS], and thus
contribute to the intraarticular production of NO
(17).
The assessment of nitrosative stress in rheumatoid
arthritis was studied by measuring the related
markers. These include serum and synovial fluid
nitrate (an indirect measure of nitric oxide
production) (11), urinary nitrate:creatinine ratio (an
assessment of endogenous nitric oxide production)
(18), serum NG-hydroxy-L-arginine (an index of
increased nitric oxide synthase activity) (19), and 3nitrotyrosine level in serum or synovial fluid (specific
marker of nitrosative damage) (20-22). Previous
studies did not assess the serum peroxynitrite level in
rheumatoid patients.
This study aimed to assess the serum levels of NO
and peroxynitrite in patients with rheumatoid
arthritis treated with disease modifying antirheumatic
drugs (DMARDs).
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Materials and methods
This study was conducted at the Department of
Pharmacology in cooperation with Al-Yarmouk
Teaching Hospital and the Department of
Biochemistry, College of Medicine, Al-Mustansiriyia
University in Baghdad, Iraq, from October 2004 to
May 2005. After obtaining permission from the local
ethics committee and informed patient consent,
patients that fulfilled the criteria of the American
College of Rheumatology (formerly The American
Rheumatism Association) (23), from the consultant
outpatient clinic at Al-Yarmouk Teaching Hospital,
were enrolled in the study. The criteria of inclusion
included sero-positive adult rheumatoid arthritis,
those treated with DMARDs [methotrexate® tablet 7.5
mg/week, chloroquine sulfate (Nivaquine)® tablet 200
mg/day, cyclosporine (Neoral)® oral solution 2
mg/day, penicillamine (Distamine)® 250 mg /day]
either individually or in combination, and the patients
were allowed freely to take nonsteroidal antiinflammatory drugs when needed. The criteria of
exclusion were concomitant diseases including
hypertension and diabetes mellitus. A consultant
rheumatologist assessed each patient clinically,
radiologically, and serologically.
Sixteen patients (12 females and 4 males) with a
median age of 50 years were included in the study. The
median duration of the disease was 5 years. The
distribution of patients in respect of taking DMARDs
was as follows: methotrexate 5, chloroquine sulfate 1,
penicillamine 1, cyclosporine A 1, and a combination
of methotrexate and chloroquine sulfate 8. The
erythrocyte sedimentation rate at the time of the study
was taken as a routine marker of disease activity. The
mean ± SD of erythrocyte sedimentation rate was 59.6
± 30.8 mm/h. In addition, 16 subjects matched to the
patient group with regard to age and gender were
allocated randomly from the staff departments at the
college of medicine. All subjects were examined and
investigated by routine laboratory tests and they
appeared healthy.
Venous blood samples were collected from patients
and healthy subjects. The sera were separated by
centrifugation (3000 rpm for 3 min) and immediately
processed for NO and peroxynitrite assay. NO in the
serum was determined as described by NavarroGonzalvez et al. (24) by measuring the concentration of
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nitrates. The reduction of nitrate to nitrite by cadmium
is the basis for this method. The Griess reaction was
used to determine the nitrite, which reacts with a Griess
reagent to form Griess chromophore. In brief, 150 μL of
serum was deproteinized by adding 250 μL of 75 mM
ZnSO4 solution, stirring and centrifuging at 10,000 ×g
for 5 min at 25 °C. Then we added 350 μL of 55 mM
NaOH and stirred and centrifuged the solution at 10,000
×g for 5 min at 25 °C. We recovered the supernatant,
which was free from turbidity, and diluted 750 μL of this
with 250 μL of glycine buffer (45g/L, pH 9.7). We then
added 2-2.5 g of freshly activated cadmium granules to
1 mL of pretreated deproteinized serum and stirred this
continuously for 10 min. After that, we transferred 200
μL of the treated serum into another tube and added
Griess reagent (750 μL of 25 mg N-naphthylenediamine
in 250 mL of distilled water and 800 μL of 5 g of
sulfanilic acid in 500 mL of 3 M HCl). The absorbance
of the sample was recorded at 340 nm by SpeCol®
spectrophotometer. The concentration of serum NO
(μmol) was calculated in respect to the standard lithium
nitrate absorbance concentration curve with a best fit
line equation of: Absorbance (O.D.) = 0.0018 + 0.0002 ×
concentration (r = 0.997).
Serum peroxynitrite level was determined according
to the method described by Beckman et al. (25), cited
by VanUffelen et al. (26). Peroxynitrite mediated
nitration of phenol, resulting in nitrophenol formation,
formed the basis of the peroxynitrite assay. In brief, 10
μL of serum was placed in a glass test tube and added to
5 mM phenol in 50 mM sodium phosphate buffer to a
final volume of 2 mL and mixed well. This was then
incubated for 2 h at 37 °C, followed by the addition 15
μL of 0.1 NaOH and mixed. We then recorded the
®
absorbance of the sample at 412 nm by SpeCol
spectrophotometer [PGH, Radi Fernesehen Electro,
Germany]. We calculated the yield of nitrophenol from
-1
-1
ε = 4400 M cm .
All the chemicals used in this work were of Analar
grade, dissolved in distilled water, and prepared
freshly at the time of assay.
The results are expressed as mean, median,
standard deviation [SD] and 95 % confidence interval.
Student’s unpaired 2-tailed “t” test and a simple
correlation test with linear least squares were used. P
≤ 0.05 was considered statistically significant.

Results
Table 1 shows the demographic characteristics of
the subjects. There was no significant difference
between the control and rheumatoid patients
regarding gender, age, body mass index, or smoking
habit.
The sero-positive rheumatoid patients treated with
DMARDs had a significantly high serum level of NO
that was more than 2-fold that of the controls and
their serum peroxynitrite level was approximated 3
times that of the controls (Table 2).
Males with rheumatoid arthritis tended to have
nonsignificantly (95% C.I. 7.85-4, P > 0.05) high
serum levels of nitric oxide as compared with females
(160.35 ± 21.746 μmol vs. 95.918 ± 48.116 μmol
respectively) while the picture is reversed with
peroxynitrite i.e. females had nonsignificantly (95%
C.I. 7.85-40.15, P > 0.05) higher values than
corresponding males [7.821 ± 4.857 μmol vs. 5.511 ±
4.184 μmol]. Patients older than 50 years had
nonsignificantly (95% C.I. 9.43-45.57, P > 0.05)
higher levels of NO (135.1 ± 31.503 μmol) and

Table 1. The characteristics of the subjects.

Controls
(n = 16)

Rheumatoid patients
treated with DMARDs
(n = 16)

Gender
Male

4

4

Female

12

12

8

9

Age (year)
<50
>50
Weight (kg)
2

Height (m )

8

7

70.3 ± 10.2

72.6 ± 14.8

1.61 ± 0.15

1.62 ± 0.12

2
Body mass index (kg/m ) 27.1 ± 5.9

27.7 ± 6.6

Smoking
Active

4

Passive

10

7

0

0

Range

–

2-15

Median

–

5

Alcohol consumption

3

Duration of illness (year)
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nonsignificantly (95% C.I. 9.43-45.57, P > 0.05) lower
peroxynitrite levels (6.454 ± 3.43 μmol) than those
under 50 years old (108.645 ± 55.292 μmol and 7.603
± 5.258 μmol respectively). There was no significant
negative correlation between the serum NO and the
duration of the disease (r = -0.0192, a = 118.39, b = -

0.229) or erythrocyte sedimentation rate (r = -0.0259,
a = 141.88, b = -0.0419) (Figure 1). Moreover,
peroxynitrite did not significantly correlate with the
duration of the disease (r = -0.172, a = 8.494, b = 0.1942) or the erythrocyte sedimentation rate (r =
0.321, a = 4.329, b = 0.04189) (Figure 2).

Table 2. Serum levels of NO and peroxynitrite.
Rheumatoid patients treated
with DMARDs (n = 16)

Controls (n = 16)
Nitrogen species
Mean

Median

SD

Mean

Median

SD

Nitric oxide (μmol)

46

48.5

15.75

116.91

131.6*

49.63

Peroxynitrite (μmol)

2.542

2.727

0.599

7.348

7.386**

4.676

* P < 0.001 (t value = 6.575)
** P < 0.001 (t value = 4.110)

200
150

Peroxynitrite (umol)

Nitric oxide (umol)

250

100
50
(a)
0
0

5

10

15

20

Duration of disease (year)

20
18
16
14
12
10
8
6
4
2
0

(a)

0

5

250

10
15
Duration of disease (year)

20

20
18
Peroxynitrite (umol)

Nitric oxide (umol)

200
150
100
50

(b)

16
(b)

14
12
10
8
6
4
2

0
0

20

40

60

80

100

120

140

Erythrocyte sedimentation rate (mm/hour)

Figure 1. Nonsignificant correlation between duration of disease
[A] or erythrocyte sedimentation rate [B] with serum
nitric oxide in sero-positive rheumatoid arthritis
patients.
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Figure 2. Nonsignificant correlation between duration of disease
[A] or erythrocyte sedimentation rate [B] with serum
peroxynitrite in sero-positive rheumatoid arthritis
patients.
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Discussion
The results of this work show overproduction of
nitrogen species in sero-positive rheumatoid patients
treated with DMARDs, reflected by significantly high
serum NO and peroxynitrite levels. Under normal
conditions iNOS activity is very low, but it is
stimulated during inflammation by cytokines such as
tumor necrosis factor (TNF-α). Functional iNOS gene
polymorphisms have been associated with
susceptibility to rheumatoid arthritis (6). This
explains the high level of NO in this study. Moreover,
the presence of peroxynitrite, a redox derivative of
NO, enhances the inflammatory response by
sustaining the nuclear localization of nuclear factorkappaB(NFκB) (27).
It is well known that the expression of inducible
NO synthase enzyme, in arthritis, is upregulated by
many proinflammatory mediators like infernos and
interleukins (28). Moreover, in rheumatoid patients
HLA-DRB1 alleles tended to trigger nitric oxide
mediated signaling events (29). The generation of
neo-antigenic determinants by reactive oxygen and
nitrogen species may contribute to epitope spreading
in autoimmunity (30). The oxidation of amino acid
by peroxynitrite increases the antigenicity of
immunoglobulin-G, generating ligands for which
autoantibodies show higher activity (30). This could
explain the high levels of nitrogen species in seropositive rheumatoid arthritis but it does not explain
the high levels in patients treated with DMARDs.
Matyska-Piekarska et al. (2006) found that the
favorable effect of DMARDs on articular damage is
related to their effects on reactive oxygen species (31).
Therefore, the results of this work show that
DMARDs seem to have no effect on reactive nitrogen
species. Recently, Gonzalez-Gay et al. (6) reported
that infliximab, a TNF-α blocker, significantly

reduced the serum levels of nitrogen species and those
who do not response to anti-TNF- α therapy could
experience arthritis that is perpetuated by the B-cell
more than the T-cell and highlighted that nitrogen
species are not the only factor involved in the
pathogenesis of rheumatoid arthritis (32).
Several authors assessed nitrosative stress in
rheumatoid patients in sera in terms of finding
significant high levels of NO (14,33-35), nitrate
(15,18), nitrite (11,16,33), and nitrotyrosin (20) or
nonsignificant changes in plasma nitrite level (36), but
there is no report about serum peroxynitrite as with
this study. The significant high serum peroxynitrite,
the product of the reaction of nitric oxide and
superoxide anion, can serve as an indicator for
simultaneous assessment of reactive oxygen and
nitrogen species.
In respect to the correlation between serum
nitrogen species levels and markers of disease activity,
the present results are in accordance with others
(16,28). Furthermore, polymorphisms in genes
coding for catalase 262CC and TNF-α 308GG but not
iNOS (NOS2A) alone or in combination influence the
activity of rheumatoid arthritis (37), i.e. no relation
between disease activity and nitrogen species as
demonstrated in this study. Therefore, it is possible to
postulate that nitrogen species are essential for the
upregulation of the inflammatory response (38) but
do not serve as a prognostic marker. It is concludeed
that rheumatoid patients treated with DMARDs have
significantly high serum nitrogen species that are
unrelated to the duration or the activity of disease.
Further research is recommended to elucidate the
difference in the magnitude of nitrogen species in
rheumatoid patients between those that are seropositive and sero-negative.
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